These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 36046840)

  • 1. Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?
    Nerone M; Grande MD; Sessa C; Colombo I
    Explor Target Antitumor Ther; 2022; 3(2):149-171. PubMed ID: 36046840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating antibody drug conjugates in the management of gynecologic cancers.
    Chelariu-Raicu A; Mahner S; Moore KN; Lorusso D; Coleman RL
    Int J Gynecol Cancer; 2023 Mar; 33(3):420-429. PubMed ID: 36878560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Drug Conjugates in Gynecologic Cancers.
    Anastasio MK; Shuey S; Davidson BA
    Curr Treat Options Oncol; 2024 Jan; 25(1):1-19. PubMed ID: 38172449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antibody-Drug Conjugates in Breast Cancer and Gynecologic Cancer].
    Saito A; Yonemori K
    Gan To Kagaku Ryoho; 2024 Jul; 51(7):695-701. PubMed ID: 39191683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evolving landscape of antibody-drug conjugates in gynecologic cancers.
    Tolcher A; Hamilton E; Coleman RL
    Cancer Treat Rev; 2023 May; 116():102546. PubMed ID: 37023499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer.
    Gonzalez-Ochoa E; Veneziani AC; Oza AM
    Clin Med Insights Oncol; 2023; 17():11795549231187264. PubMed ID: 37528890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload.
    Kondrashov A; Sapkota S; Sharma A; Riano I; Kurzrock R; Adashek JJ
    Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in antibody-drug conjugates for gynecologic malignancies.
    Tymon-Rosario J; Gorman M; Richardson DL; Washington C; Santin AD
    Curr Opin Obstet Gynecol; 2023 Feb; 35(1):6-14. PubMed ID: 36484278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-Drug Conjugates in Gynecologic Cancer.
    Karpel HC; Powell SS; Pothuri B
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e390772. PubMed ID: 37229642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives.
    Martín-Sabroso C; Lozza I; Torres-Suárez AI; Fraguas-Sánchez AI
    Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-drug conjugates for the treatment of ovarian cancer.
    Calo CA; O'Malley DM
    Expert Opin Biol Ther; 2021 Jul; 21(7):875-887. PubMed ID: 32463296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer.
    Wang AJ; Gao Y; Shi YY; Dai MY; Cai HB
    Front Pharmacol; 2022; 13():1093666. PubMed ID: 36618922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
    O'Malley DM; Matulonis UA; Birrer MJ; Castro CM; Gilbert L; Vergote I; Martin LP; Mantia-Smaldone GM; Martin AG; Bratos R; Penson RT; Malek K; Moore KN
    Gynecol Oncol; 2020 May; 157(2):379-385. PubMed ID: 32081463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Therapeutic Advances in Gynecologic Oncology: A Review.
    Wilson EM; Eskander RN; Binder PS
    Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tisotumab vedotin for the treatment of cervical carcinoma.
    Song X; Li R; Wang H; Song P; Guo W; Chen ZS
    Drugs Today (Barc); 2022 May; 58(5):213-222. PubMed ID: 35535813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
    Campos MP; Konecny GE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Society of Gynecologic Oncology Journal Club: Controversial conversations in Gynecologic cancer - The ABCs of ADCs (Antibody drug Conjugates).
    Martin J; Zacholski E; O'Cearbhaill R; Matulonis U; Chen L
    Gynecol Oncol Rep; 2023 Feb; 45():101141. PubMed ID: 36818197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
    Moore KN; O'Malley DM; Vergote I; Martin LP; Gonzalez-Martin A; Malek K; Birrer MJ
    Gynecol Oncol; 2018 Oct; 151(1):46-52. PubMed ID: 30093227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revisiting antibody-drug conjugates and their predictive biomarkers in platinum-resistant ovarian cancer.
    El Bairi K; Al Jarroudi O; Afqir S
    Semin Cancer Biol; 2021 Dec; 77():42-55. PubMed ID: 33812984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-drug conjugates for ovarian cancer: current clinical development.
    Stewart D; Cristea M
    Curr Opin Obstet Gynecol; 2019 Feb; 31(1):18-23. PubMed ID: 30531606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.